125 related articles for article (PubMed ID: 20886414)
1. Growth factor receptors gene expression and Akt phosphorylation in benign human thyroid nodules are unaffected by chronic thyrotropin suppression.
Sponziello ML; Bruno R; Durante C; D'Agostino M; Corradino R; Giannasio P; Ciociola E; Ferretti E; Maranghi M; Verrienti A; De Toma G; Filetti S; Russo D
Horm Metab Res; 2011 Jan; 43(1):22-5. PubMed ID: 20886414
[TBL] [Abstract][Full Text] [Related]
2. Functional roles of the bone morphogenetic protein system in thyrotropin signaling in porcine thyroid cells.
Suzuki J; Otsuka F; Takeda M; Inagaki K; Miyoshi T; Mimura Y; Ogura T; Doihara H; Makino H
Biochem Biophys Res Commun; 2005 Feb; 327(4):1124-30. PubMed ID: 15652513
[TBL] [Abstract][Full Text] [Related]
3. Levothyroxine suppressive therapy in the medical management of nontoxic benign multinodular goiter.
Celani MF
Exp Clin Endocrinol; 1993; 101(5):326-32. PubMed ID: 8299711
[TBL] [Abstract][Full Text] [Related]
4. Modulation of thyroid-specific gene expression in normal and nodular human thyroid tissues from adults: an in vivo effect of thyrotropin.
Bruno R; Ferretti E; Tosi E; Arturi F; Giannasio P; Mattei T; Scipioni A; Presta I; Morisi R; Gulino A; Filetti S; Russo D
J Clin Endocrinol Metab; 2005 Oct; 90(10):5692-7. PubMed ID: 16076943
[TBL] [Abstract][Full Text] [Related]
5. [Non-toxic nodular goiter: treatment and follow-up].
Mereu P; Scala M; Schenone F; Schenone G; Comandini D; Gipponi M; Margarino G
Acta Otorhinolaryngol Ital; 1995 Aug; 15(4):301-4. PubMed ID: 8928662
[TBL] [Abstract][Full Text] [Related]
6. L-thyroxine-treated patients with nodular goiter have lower serum TSH and lower frequency of papillary thyroid cancer: results of a cross-sectional study on 27 914 patients.
Fiore E; Rago T; Provenzale MA; Scutari M; Ugolini C; Basolo F; Di Coscio G; Miccoli P; Grasso L; Pinchera A; Vitti P
Endocr Relat Cancer; 2010 Mar; 17(1):231-9. PubMed ID: 20167722
[TBL] [Abstract][Full Text] [Related]
7. Levothyroxine suppressive therapy is partially effective in treating patients with benign, solid thyroid nodules and multinodular goiters.
Lima N; Knobel M; Cavaliere H; Sztejnsznajd C; Tomimori E; Medeiros-Neto G
Thyroid; 1997 Oct; 7(5):691-7. PubMed ID: 9349571
[TBL] [Abstract][Full Text] [Related]
8. Exogenous and endogenous suppression of thyroid-stimulating hormone induces similar effects on thyroidal iodothyronines.
Solter M; Tislarić D; Posavec L; Pegan B; Petric V
Exp Clin Endocrinol; 1991 Mar; 97(1):81-90. PubMed ID: 1864317
[TBL] [Abstract][Full Text] [Related]
9. Insulin-like growth factor-binding protein-3 (IGFBP-3) but not insulin-like growth factor-I (IGF-I) remains elevated in euthyroid TSH-suppressed Graves' disease.
Wan Nazaimoon WM; Khalid BA
Horm Metab Res; 1998 Apr; 30(4):213-6. PubMed ID: 9623636
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of administering 0.2 mg of recombinant human TSH for two consecutive days as an adjuvant to therapy with low radioiodine doses in elderly out-patients with large nontoxic multinodular goiter.
Giusti M; Cappi C; Santaniello B; Ceresola E; Augeri C; Lagasio C; Minuto F
Minerva Endocrinol; 2006 Sep; 31(3):191-209. PubMed ID: 17213787
[TBL] [Abstract][Full Text] [Related]
11. Long-term changes in nodular goiter: a 5-year prospective randomized trial of levothyroxine suppressive therapy for benign cold thyroid nodules.
Papini E; Petrucci L; Guglielmi R; Panunzi C; Rinaldi R; Bacci V; Crescenzi A; Nardi F; Fabbrini R; Pacella CM
J Clin Endocrinol Metab; 1998 Mar; 83(3):780-3. PubMed ID: 9506726
[TBL] [Abstract][Full Text] [Related]
12. The value of L-thyroxine in the supressive therapy of euthyroid nodules and in the prevention of post-thyroidectomy recurrences.
Koloğlu S; Başkal N; Koloğlu LB
Endocrinologie; 1988; 26(2):89-98. PubMed ID: 3413442
[TBL] [Abstract][Full Text] [Related]
13. T3-release from autonomously functioning thyroid nodules in vitro.
Poertl S; Kirner J; Saller B; Mann K; Hoermann R
Exp Clin Endocrinol Diabetes; 1998; 106(6):489-93. PubMed ID: 10079030
[TBL] [Abstract][Full Text] [Related]
14. Postintervention serum TSH levels may be useful to differentiate patients who should undergo levothyroxine suppressive therapy after thyroid surgery for multinodular goiter in a region with moderate iodine deficiency.
Rotondi M; Amato G; Del Buono A; Mazziotti G; Manganella G; Biondi B; Sinisi AM; Santini L; Bellastella A; Carella C
Thyroid; 2000 Dec; 10(12):1081-5. PubMed ID: 11201853
[TBL] [Abstract][Full Text] [Related]
15. Analysis and prevention of recurrent goiter.
Kraimps JL; Marechaud R; Gineste D; Fieuzal S; Metaye T; Carretier M; Barbier J
Surg Gynecol Obstet; 1993 Apr; 176(4):319-22. PubMed ID: 8460405
[TBL] [Abstract][Full Text] [Related]
16. Association of serum paraoxonase activity with insulin sensitivity and oxidative stress in hyperthyroid and TSH-suppressed nodular goitre patients.
Yavuz DG; Yüksel M; Deyneli O; Ozen Y; Aydin H; Akalin S
Clin Endocrinol (Oxf); 2004 Oct; 61(4):515-21. PubMed ID: 15473886
[TBL] [Abstract][Full Text] [Related]
17. Levothyroxine replacement therapy after thyroid surgery.
Verhaert N; Vander Poorten V; Delaere P; Bex M; Debruyne F
B-ENT; 2006; 2(3):129-33. PubMed ID: 17067083
[TBL] [Abstract][Full Text] [Related]
18. Evaluation and management of multinodular goiter.
Hurley DL; Gharib H
Otolaryngol Clin North Am; 1996 Aug; 29(4):527-40. PubMed ID: 8844728
[TBL] [Abstract][Full Text] [Related]
19. [Therapy with L-thyroxine in thyroid struma. Study with ultrasonic evaluation].
Peta M; Cartasegna S; Fabiani MP; Macchi R; Vecchi G; Costantino D
Recenti Prog Med; 1989 Jun; 80(6):320-5. PubMed ID: 2672195
[TBL] [Abstract][Full Text] [Related]
20. Highly sensitive determination of TSH in the follow-up of TSH-suppressive therapy of patients with differentiated thyroid cancer.
Mann K; Saller B; Mehl U; Hörmann R; Moser E
Nuklearmedizin; 1988 Feb; 27(1):24-8. PubMed ID: 3368333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
